Abstract Library

#4531 The role of metabolism in neuroendocrine tumour cell models and patients

Introduction: It is recognised that the adipose tissue plays a major role in cancer through a metabolic coupling that supports tumour cell growth. Recent evidence suggests that altered metabolic pathways drive the development and influence the clinical outcomes of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Calabrese C

Authors: Calabrese C, Dellavalle S, Miserocchi G, Gabellone S, Spadazzi C,

Keywords: tumour metabolism, adipocytes, RNA-sequencing, GEP-NET,

#4358 Patients with neuroendocrine tumour after surgical treatment and therapy with somatostatin analogues: Comparison of body mass index (BMI)

Introduction: Neuroendocrine tumours (NET) are heterogeneous neoplasms, commonly arising in the gastroenteropancreatic tract (GEP-NET) or bronchopulmonary (L-NET). Surgery is the first line treatment, when possible, while somatostatin analogues (SSA) are the main medical therapy. However, the impact of these therapies on anthropometric indices has not been fully explored.

Conference:

Presenting Author:

Authors: Di Iasi G, Benevento E, Cannavale G, Di Nola M, Liccardi A,

Keywords: BMI, NET, SSA, SURGERY, WEIGHT LOSS, GEP-NET, LUNG NET, WAIST CIRCUMFERENCE, HIP CIRCUMFERENCE,

#4343 Ga68-DOTATATE imaging on a state-of-the-art total-body PET/CT scanner with reducing administered activity

Introduction: Long-field of view PET/CT scanners allows total body scanning resulting higher sensitivity than traditional PET/CT scanners offering possible lower dose and faster scans.

Conference:

Presenting Author: Santillan N

Authors: Navalkissoor S, Santillan N, Chowdhury A, Ferreira B, Toumpanakis C,

Keywords: SSR, Ga68 DOTATATE, Neuroendocrine tumour, Quadra,

#4181 High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumors using somatostatin analogues

Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients (pts) with gastoenteropancreatic (GEP) neuroendocrine tumors (NETs) treated with somatostatin analogues (SSAs) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements (micronutrients) are not part of the GLIM criteria but frequently reported in pts with GEP-NETs treated with SSAs.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,

#4173 The global leadership into malnutrition criteria reveals a high percentage of malnutrition which negatively influences overall survival in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogues

Introduction: Patients (pts) with GEP-NETs treated with somatostatin analogues (SSA’s) are at risk of malnutrition. This has been reported, using weight loss or body mass index (BMI) only. The Global leadership into malnutrition (GLIM) criteria include weight loss, BMI and sarcopenia. In pts with other types of cancer the presence of malnutrition, has a negative effect on overall survival (OS). In pts with GEP-NETs treated with SSA’s this has not been explored before.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,